In short
This article summarizes several clinical trials investigating the use of pneumococcal polysaccharide serotype 10A conjugate vaccine, often as part of multi-valent pneumococcal vaccines, for preventing pneumococcal infections. The trials evaluate the safety, immune responses, and effectiveness of these vaccines in different populations, including healthy adults, children, and those at increased risk of pneumococcal disease. Key aspects examined include vaccine-induced antibody levels, opsonophagocytic activity, and protection against pneumococcal pneumonia.
At a glance
- Vaccine Types
- Multi-valent pneumococcal conjugate vaccines including serotype 10A (e.g. 20-valent, 21-valent)
- Study Populations
- Healthy adults, children/adolescents at risk, adults ≥65 years
- Primary Outcomes
- Safety, immunogenicity, opsonophagocytic activity, prevention of pneumococcal pneumonia
- Key Measurements
- Antibody levels, OPA titers, adverse events, vaccine effectiveness
- Study Designs
- Randomized controlled trials, open-label studies, test-negative designs
- Comparators
- Other pneumococcal vaccines (e.g. PPSV23), placebo, or no vaccination
- Follow-up Periods
- Ranging from 30 days post-vaccination to several months or years
- Special Considerations
- Co-administration with other vaccines, effects in high-risk groups, long-term protection
What is Pneumococcal Polysaccharide Serotype 10A?
Pneumococcal Polysaccharide Serotype 10A is a specific type of bacterial capsule component found in certain strains of Streptococcus pneumoniae, also known as pneumococcus. This bacterium is responsible for various infections, including pneumonia, meningitis, and bloodstream infections. Serotype 10A refers to one of the many variants of the pneumococcal bacteria, each with a unique polysaccharide coating that helps it evade the immune system.
Role in Pneumococcal Vaccines
Pneumococcal Polysaccharide Serotype 10A plays a crucial role in modern pneumococcal vaccines. It is included as one of the serotypes targeted by advanced pneumococcal conjugate vaccines. In these vaccines, the polysaccharide is chemically linked (conjugated) to a carrier protein, typically CRM197, which enhances the immune response, especially in young children and older adults.
Vaccine Formulations
Several pneumococcal vaccines containing Serotype 10A are currently in use or under development:
- Apexxnar (20-valent pneumococcal conjugate vaccine): This vaccine includes Pneumococcal Polysaccharide Serotype 10A among its 20 serotypes, all conjugated to CRM197 and adsorbed on aluminum phosphate.
- V116 (21-valent pneumococcal conjugate vaccine): An investigational vaccine that also includes Serotype 10A among its targeted serotypes.
Target Population
Pneumococcal vaccines containing Serotype 10A are primarily designed for:
- Adults aged 65 years and older
- Adults aged 18-64 with certain risk factors or chronic conditions
- Children and adolescents at increased risk of pneumococcal disease
These vaccines aim to protect against invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP) caused by the vaccine serotypes, including Serotype 10A.
Effectiveness and Immune Response
The effectiveness of vaccines containing Pneumococcal Polysaccharide Serotype 10A is typically measured through:
- Opsonophagocytic activity (OPA): This measures the ability of antibodies to facilitate the killing of bacteria by immune cells.
- Immunoglobulin G (IgG) levels: These indicate the concentration of specific antibodies produced against the serotype.
Clinical trials have shown that vaccines containing Serotype 10A can elicit a significant immune response, with many participants achieving a four-fold or greater rise in OPA titers and IgG concentrations after vaccination.
Safety Profile
The safety of pneumococcal vaccines containing Serotype 10A is closely monitored in clinical trials. Common side effects may include:
- Injection site reactions (pain, redness, swelling)
- Fatigue
- Headache
- Muscle pain
- Joint pain
Serious adverse events are rare, and the vaccines are generally considered safe for the recommended populations.
Ongoing Research
Several clinical trials are currently underway to further evaluate the effectiveness and safety of pneumococcal vaccines containing Serotype 10A:
- Studies comparing the immune response of newer vaccines to existing ones
- Investigations into the vaccine's effectiveness against community-acquired pneumonia
- Research on the vaccine's performance in specific populations, such as those with chronic medical conditions
These ongoing studies aim to provide more comprehensive data on the role of Pneumococcal Polysaccharide Serotype 10A in preventing pneumococcal diseases across various age groups and risk categories.